KAHR

1 stories about KAHR
ירון פרג מנכל כאהר מדיקל

KAHR announced $46.5 million funding round to advance its immunotherapeutic pipeline

16.06.21|James Spiro
The round will be used to advance the clinical development of KAHR’s lead product candidate, DSP107